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 Tissue proteomics:
a new investigative tool
for renal biopsy analysis 
 John R.  Sedor 1 , 2 , 3 
 Renal biopsy is viewed as the gold standard for diagnosis and 
management of many kidney diseases, especially glomerulopathies. 
However, the histopathological descriptions currently used in clinical 
practice often are neither diagnostic nor prognostic. The paper 
by Sethi  et al. highlights the availability of a newer investigative 
tool that can be used to better define pathogenesis and, perhaps 
more important, to discover  robust biomarkers of kidney disease 
cause and outcome. 
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 Renal biopsy: more than a picture 
 Renal biopsy has long been used to di-
agnose and manage both acute and 
chronic kidney diseases, especially re-
nal dysfunction caused by glomerular 
injury. Despite elegant descriptions by 
talented investigative and clinical renal 
pathologists, the impact of renal biopsy 
on patient outcomes remains subopti-
mal. From a clinical perspective, his-
topathology  oB en is neither diagnostic 
nor prognostic and fails to predict re-
sponse to therapy of individuals within a 
given glomerular histopathological cat-
egory. Less-than-de& nitive data gleaned 
from kidney  biopsies may re% ect the 
heterogeneity of pathogenetic molecu-
lar mechanisms, that generate clinically 
indistinguishable histology. We have 
learned from molecular genetics that 
although diE erent  genetic variants can 
cause identical kidney pathologies, the 
treatments should be diE erent. For ex-
ample, patients with focal segmental 
glomerulosclerosis on biopsy can be 
steroid-responsive if the  mutation is in 
the gene encoding phospholipase C-ε 
but steroid-resistant if the mutation is 
in the gene encoding podocin or the ion 
 channel TRPC6. In addition to genetic 
mechanisms, molecular characteriza-
tion of kidney biopsies using  in situ 
hybridization and immunohistochem-
istry to characterize the diE erentiation 
state of endogenous kidney cells,  in% ux 
of leukocytes, and local networks of 
more advanced forms of the complex, can 
occur in the circulation of CKD patients 
needs to be con& rmed in future studies. 
In addition, the pathway by which the 
formed fetuin – mineral complex is cleared 
from serum also awaits elucidation. 
Finally, we would like to mention a 
 practical problem: the method for identi-
fying these complexes is currently too 
demanding for the majority of investiga-
tors. Development of a new assay that 
specifically measures fetuin – mineral 
complex would further expand this & eld 
of research. 
 In conclusion, Matsui  et al. 8 report a 
promising eE ect of fetuin-A to prevent 
vascular calci& cation by forming fetuin –
 mineral complex in an experimental model 
of uremia.  e formation of these com-
plexes may re% ect a response against extra-
osseous calci& cation stress and may lead to 
novel approaches to identifying individu-
als at high risk for vascular calci& cation. 
Future studies should examine whether 
measurement of fetuin – mineral complex 
can be used as a potential biomarker to 
guide strategies for the treatment of min-
eral and bone disorder in CKD patients. 
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presence of proteins using speci& c pro-
teins, the proteomic data present a char-
acteristic signature of  proteins within 
normal and diseased  glomeruli. 
 What did we learn? Some results were 
expected. Proteins that regulate and result 
from C3 convertase activity were identi-
& ed. A more surprising observation is that 
terminal complement components C5, 
C6, C7, and C8 were speci& cally identi& ed 
in the glomeruli of MPGN type II patients, 
suggesting that in addition to  uncontrolled 
activation of the alternative complement 
pathway, MPGN type II is mediated by 
excessive % uid-phase production of the 
terminal complement complex. These 
results highlight a previously unknown 
mechanism of glomerular injury in 
MPGN type II and suggest that reducing 
fluid-phase activation of  the terminal 
complement complex may be a new ther-
apeutic approach for a rare, untreatable 
disease that targets children and young 
adults. Finally, several proteins, such as 
 cytokines and growth factors has shown 
that the same histology may result from 
diE erent molecular mechanisms. Given 
that histopathological uniformity can 
result from heterogeneous molecular 
mechanisms — a disconnect between 
 phenotype and pathogenetic mechanism 
that is di6  cult to sort out with standard 
clinical and demographic tools — more 
robust biomarkers are needed for care of 
kidney disease patients. 
 Sethi and his colleagues 1 (this issue) 
add to the investigative toolbox used to 
extract meaningful information from 
renal biopsy. Dense deposit disease, also 
known as membranoproliferative 
 glomerulonephritis type II (MPGN 
type II), is characterized by thickening of 
the  glomerular basement membrane, 
hypercellularity, and matrix expansion. 
 e hallmark of MPGN type II is the pres-
ence of electron-dense deposits within the 
lamina densa layer of the glomerular 
basement membrane  ( Figure 1 ) that may 
be visible by conventional eosin and peri-
odic acid – Schiff  stains. 2 Compelling 
 evidence from both patients and experi-
mental models demonstrates that MPGN 
type II results from dysregulation of the 
alternative pathway of complement acti-
vation caused by either an antibody that 
permits continued C3 convertase activity 
or  absence of % uid-phase regulators of C3 
convertase activity. 2,3 Despite these data 
on mechanism, the composition of the 
dense deposits has remained unclear, and 
treatment options are  limited. 
 Sethi  et al. 1 applied proteomic method-
ologies to characterize the component 
proteins of the dense deposits and further 
clarify mechanisms of this disease. 
Glomeruli were laser-microdissected 
from formalin-& xed, para6  n-embedded 
sections, and the glomerular proteins 
were identified by mass spectrometry 
 ( Figure 2 ). The authors demonstrate 
 a typical protein pro& le that resulted from 
this analysis.  e experimental design 
compares glomerular proteins identi& ed 
in patients with MPGN type II with pro-
teins identi& ed in glomeruli laser-micro-
dissected from two control groups: living 
related transplant protocol biopsies and 
patients with primary (type I) and sec-
ondary immune complex MPGN.  In con-
trast to targeted analyses to assess for the 
 Figure 1  |  Electron micrograph showing intramembranous electron-dense deposits with 
ribbon-like thickening of glomerular capillary walls (arrow ) . The mesangium is expanded by 
increased matrix and cells. 
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 Figure 2  |  Work flow for tissue proteomics. A kidney biopsy is formalin-fixed and paraffin-
embedded (FFPE) by appropriate protocols. Kidney tissue sections are then processed for 
either histopathological evaluation or tissue proteomics. The kidney structures of interest 
are laser-microdissected; proteins are extracted and then subjected to mass spectrometry 
methodologies for identification. 
 commentar y 
878   Kidney International (2009) 75 
Whole-genome expression analysis is an 
analytic methodology familiar to the 
nephrology community through its appli-
cation to both experimental models of 
kidney disease and human kidney biopsy 
specimens. 8,9 Rather than extraction of 
RNA, proteins are extracted from target 
tissues and protein signatures are deter-
mined by mass spectrometry aB er peptide 
separation using both gel-free and gel-
based technologies. 10,11 
 Advantages to the use of tissue pro-
teomics for biomarker discovery include 
the ability to laser-microdissect speci& c 
cell populations within tissue structures 
and application of stringent statistical 
methodologies to the analysis of the pep-
tides in order to determine the likelihood 
that a speci& c protein of interest is indeed 
present in the target tissue. Issues with 
less-than-optimal antibody or RNA probe 
speci& city may be circumvented by the 
optimization of tryptic peptide coverage 
of protein sequences, which greatly 
increases con& dence in the conclusion 
that a particular molecule is present 
within the diseased tissue . In addition, by 
de& nition, both immunohistochemistry 
and  in situ hybridization are hypothesis-
driven methodologies. When using these 
methods, the investigator designs experi-
ments to assess the role of a speci& c pro-
tein or proteins in a disease process. In 
contrast, tissue proteomics is a discovery-
based methodology that is not biased by 
preconceived ideas. As with any new 
technology, the analytic validity of tissue 
proteomic technologies must be deter-
mined.  e reproducibility and compara-
bility of proteomes generated from 
specimens prepared with different 
approaches (for example, fresh versus 
& xed tissue) must be ascertained. Com-
parisons between limited sample sets of 
& xed and fresh tissues suggest that archi-
val tissue provides reasonable representa-
tion of the tissue proteome. 7,11,12 The 
eE ects  of sample age on protein identi& -
cation have yet to be assessed — a critical 
technical issue given the longevity of 
some available kidney biopsy collections. 
Completeness of proteome coverage also 
needs to be considered. A reasonable 
assessment of the sensitivity and speci& -
city of protein pro& les could be addressed 
by comparing the proteome and mRNA 
apolipoprotein E, are reproducibly present 
in glomeruli of MPGN type II patients. 
The biological  significance of this 
 observation is unclear, but associations 
between polymorphisms in the gene en-
coding apolipoprotein E and  nephropathy 
 phenotypes have been reported in both 
 diabetic and nondiabetic patients and may 
directly or indirectly regulate  nephropathy 
pathogenesis. 4,5 
 Tissue proteomics 
  e methodologies used by Sethi  et al. 1 
 represent an emerging investigative tool 
in the analysis of tissue specimens that 
has resulted from the compelling need 
for development of protein biomarkers 
with mechanistic, diagnostic, and thera-
peutic potential. 6 Biomarker discovery 
has focused on easily accessible analytes 
such as serum, plasma, urine, and saliva, 
but the identi& cation of novel biomarkers 
in these biological specimens that have 
analytical validity, clinical validity, and 
clinical utility has been disappointing. 
 e failure to identify biomarkers with 
clinical impact results from the com-
plexity of identifying low- abundance 
molecules in % uids dominated by high 
background concentrations of proteins, 
such as albumin in urine. Tissue pro-
teomics is based on the premise that bi-
omarker discovery will be facilitated by 
analysis of the primary site of pathology, 
in this case the glomerulus. Once novel 
molecular markers have been identi& ed 
and validated with the use of tissue sam-
ples, more targeted analytic approaches 
with appropriate dynamic ranges to 
identify low-abundance molecules can 
be applied to easily accessible samples 
such as urine or plasma. 6,7 Tissue pro-
teomics has been advanced by recent 
technical developments that permit ex-
traction analysis by mass spectrometry 
from formalin-& xed, para6  n- embedded 
tissues, 7 which makes analysis of large 
archives of kidney biopsy material fea-
sible and allows assembly of su6  cient 
sample sizes for more robust validation 
of biomarker discoveries in glomerular 
diseases. 
 Conceptually, tissue proteomic meth-
odologies are straightforward, analo-
gous to the use of tissue specimens for 
 comprehensive gene expression analysis. 
expression pro& le from the same sample. 
As is typical of all  ‘ -omic ’  technologies, 
quantitative comparisons of protein 
abundance between samples remain 
problematic.  Determining the range of 
stochastic variation in protein abundance 
in normal tissues needs to be assessed, 
and the utility of tissue proteomics for 
qualitative comparisons between normal 
and diseased human tissue specimens has 
yet to be demonstrated. However, meth-
odologies that do not require sample 
labeling are being developed for com-
parative tissue proteomics and are being 
applied to tumor specimens. 10 
 Issues and challenges 
  e prospect that tissue proteomics can 
be used by the renal community for 
discovery of novel diagnostic and prog-
nostic biomarkers is exciting. With the 
advancement in protein extraction and 
mass spectrometric analysis of laser-
microdissected, formalin-& xed, paraf-
& n-embedded tissue sections, archival 
collections of renal biopsy specimens are 
available for discovery-based bio marker 
research. However, we also face chal-
lenges in applying discovery technolo-
gies to kidney diseases. Most  important, 
development of a robust, multicenter 
investigative infrastructure that facili-
tates collection of phenotypic data and 
bi ological samples, including kidney bi-
opsy specimens, using uniform protocols 
will be necessary for biomarker identi& -
cation and validation.  e paper by Sethi 
 et al. 1 highlights this critical need. Only 
eight MPGN type II biopsies were ana-
lyzed. Biomarker discovery and valida-
tion requires much larger sample sets for 
study — a problem, given that many kid-
ney diseases meet the criteria for charac-
terization as rare diseases . Nephrologists 
lag behind our colleagues in oncology 
and HIV medicine in developing the bi-
orespositories and clinical cohorts nec-
essary to promote discovery and rapidly 
test new diagnostic  modalities on kidney 
disease patient outcomes.  Implementing 
strategies to address these needs will 
undoubtedly improve understanding 
of kidney disease pathogenesis and fa-
cilitate new approaches to the diagnosis 
and  management of patients with kidney 
diseases. 
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